Introduction
============

Nasopharyngeal carcinoma (NPC), a malignancy with an inimitable geographical distribution, is uncommon in Western countries [@B1], but is highly endemic in Southeast China [@B2]. More than 70% of patients presented with locoregionally advanced disease at their initial diagnosis [@B3], [@B4], and prognosis is still unsatisfactory for these patients although radiotherapy techniques has been greatly reformed [@B1]. Concurrent chemoradiotherapy (CCRT) is the present standardized therapy for locoregionally advanced NPC [@B5]-[@B11]. However, there is increasing evidence showing that CCRT alone may be inadequate for absolute patients at higher risk, especially those with late clinical stage diseases who have a high potential for recurrence and metastasis [@B12]. Therefore, preferable therapeutic regimens are urgently demanded to further improve the therapeutic outcomes of patients with locoregionally advanced NPC.

Previous study revealed the epidermal growth factor receptor (EGFR) was highly expressed in 80% of locoregionally advanced NPC disease and correlated with poor survival [@B13]. Cetuximab, an anti-EGFR antibody, has been proven to improve survival outcomes of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when combined treatment of cetuximab and radiotherapy (RT) was delivered [@B14]. It has been reported that the growth inhibitory effect of cisplatin can be improved by cetuximab in NPC cell lines [@B15]. Ma et al. have shown a Phase II clinical trial [@B16], which is the first study to have incorporated cetuximab into chemoradiotherapy for locoregionally advanced NPC. Concurrent treatment of cetuximab, weekly cisplatin, and intensity modulation radiated therapy (IMRT) is believed to be a feasible strategy. Our previous work had observed that for locoregionally advanced NPC patients concurrent administration of cetuximab, chemotherapy, and IMRT was effective and tolerated [@B17]. Until now, no randomized controlled clinical trial has been proved the effectiveness of that combined treatment. Accordingly, it is still undecided whether patients of locoregionally advanced NPC can benefit from the combination of CCRT plus C.

Therefore, we conducted this retrospective investigation to compare the efficacies and toxicities of CCRT plus C with CCRT alone in locoregionally advanced NPC patients using the propensity score-matching (PSM) method, which is usually conceptualized to be imitated randomized trials.

Materials and method
====================

Patients
--------

There were 681 consecutive patients with newly diagnosed stage III-IVB NPC between January 2010 and December 2014 were included in this retrospective study. All disease was non-keratinized squamous cell carcinoma. Among them, 75 underwent CCRT with cetuximab and 606 received CCRT alone. All patients had entire assessments before treatment, including history, physical examinations, hematology and biochemistry profiles, abdominal sonography, electrocardiogram (ECG), chest radiography, magnetic resonance imaging (MRI) of the neck and nasopharynx, fiber optic nasopharyngoscopy with biopsy, and technetium-99m-methylene diphosphonate (Tc-99-MDP) whole-body bone scans. Based on these examinations, patients were restaged according to the seventh edition of the American Joint Committee on Cancer/International Union against Cancer (AJCC/UICC) staging system. This study was approved by the the Research Ethics Committee of Jiangsu Cancer Hospital. Written informed consent was obtained from all the patients before treatment. All methods of this study were performed in accordance with the relevant guidelines and regulations.

Treatments
----------

The nasopharyngeal and neck tumor of all patients were treated by intensity modulation radiated therapy (IMRT), and 9-11 radiation fields were used for the IMRT. The prescribed doses were 66-75 Gy at 2.10-2.25 Gy/fraction to the planning target volume (PTV) of the primary gross tumor volume, 64-72 Gy per 28-33 fractions to the PTV of the involved lymph nodes volume, 60-62 Gy per 28-31 fractions to the PTV of the high-risk clinical target volume, and 50-52 Gy per 25-30 fractions to the PTV of the low-risk clinical target volume. Salvage treatments (chemotherapy, surgery or brachytherapy) were supplied in recorded recurrences or residual diseases whenever possible. Radiotherapy boost after primary external radiotherapy was received in 11% of these patients.

During the period of this study, official guidelines suggested CCRT for stage III-IVb with or without induction/adjuvant chemotherapy, and it was specified by the seventh editions of the AJCC/UICC TNM staging system of NPC. Overall, 75 patients in the CCRT plus C group received two cycles of concurrent chemotherapy consisting of paclitaxel and nedaplatin (TP). Among 606 patients without cetuximab, 9/606 (1.5%) were treated with RT only and 597/606 (98.5%) received RT and chemotherapy (concurrent alone). In our institution, concurrent chemotherapy regimens included docetaxel (70 mg/m^2^ d1) with cisplatin (60 mg/m^2^ d1-3) (TP), or 3-weekly cisplatin (80 mg/m^2^ d1-3)/nedaplatin (80 mg/m^2^ d2-4).

The therapy regimen of CCRT with cetuximab was determined by our previous study [@B17]. From the first day of radiotherapy, Cetuximab was used at a 250mg/m2 on a weekly basis (400mg/m2 initial dose) for 7 times. Cetuximab was given by intravenous infusion over 120 min in the first week and over 60 min in the successive radiotherapy weeks.

Toxicity and Follow-up
----------------------

Acute and late toxicities were graded in term of the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0 and the Radiation Therapy Oncology Group (RTOG) Late Radiation Morbidity Scoring Criteria, respectively [@B18].

The follow-up was counted from the day of first treatment to the day of last examination or death. In Jiangsu Cancer Hospital a standard follow-up contains complaints query, physical examinations, indirect or direct nasopharyngoscopy, abdominal sonography and chest x-ray. It was demanded with head and neck MRI every three months in the first three years, then MRI every six months after three years. Except for recurrence at the skull base, which was confirmed by bone erosion on MRI, all local recurrences were identified by soft-tissue swelling in MRI of the nasopharynx fiber optic endoscopy and diagnosed by biopsy. We defined distant metastases using symptoms, physical examinations, and bone scan, CT scan, chest X-ray, abdominal sonography, and MRI. We diagnosed the regional recurrences using biopsy, neck MRI and clinical examination.

Statistical analysis
--------------------

PSM method [@B19] was adopted to match patients between these two groups at a 1:2 ratio using the following factors: gender, age, histology, body mass index (BMI), titers of immunoglobulin A against early antigen (EBV-EA-lgA) and immunoglobulin A against viral capsid antigen (EBV-VCA-lgA) of the Epstein-Barr (EB) virus, chemotherapy regimen, T-stage, and N-stage. Covariate balances between the 2 groups were checked by the chi-squared test (categorical variable), t-test (continuous variable), or Fisher\'s exact test as appropriate.

Progression-free survival (PFS), overall survival (OS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were analyzed using the Kaplan-Meier method and compared with the log-rank test. PFS was calculated from the first day of treatment to the day of disease progression or death from any cause; OS, to death or the last examination; LRFS, to the day of locoregional failure; and DMFS, to the day of metastasis. Backward exclusion of negligible explicative variables were implemented to analyze for independent significance using Cox proportional hazards model to implement multivariate analyses.

The statistical analyses were executed by the SPSS 23.0 (Chicago, IL, USA) and R software version 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria; [www.r-project.org](http://www.r-project.org)). Two-sided *P* values \<0.05 was considered significant.

Results
=======

Patients selection
------------------

There were 681 patients included in this study. The median duration of follow-up was 45.3 months. Statistically marked diversities were found regarding age (*P* \< 0.001), EBV-EA-lgA (*P* = 0.034), T-stage (*P* = 0.004), and N-stage (*P* = 0.033) when stratifying patients based on initial treatment (CCRT + C vs CCRT). After matching, 150 (66.7%) patients were treated with CCRT and 75 (33.3%) with CCRT + C were selected, and balanced features were also studied (containing the mean age, sex, BMI, histology, EBV-EA-lgA and EBV-VCA-lgA titers, T-stage, N-stage, clinical stage). Table [1](#T1){ref-type="table"} shows the the baseline characteristics of patients between these two groups.

Survival outcomes
-----------------

In the original unmatched cohort of 681 patients, the median follow-up time was 43.9 months (5.4-78.6 months) for the CCRT arm and 41.0 months (6.0-71.2 months) for the CCRT + C arm, respectively. The 3-year PFS (83.9% vs 76.6 %, *P* = 0.153), OS (86.4 % vs 91.4%, *P* = 0.284), LRFS (93.2% vs 98.6%, *P* = 0.784), and DMFS (84.3% vs 83.9%, *P* = 0.918) rates were comparable between CCRT alone and CCRT plus C groups (Figure [S1](#SM0){ref-type="supplementary-material"} in the Supplementary Appendix, available at Journal of Cancer).

In the propensity-matched regiment of 225 patients, 41.0 months (6.0-71.2 months) for the CCRT plus C arm and 43.6 months (5.6-75.3 months) for the CCRT arm were shown in the median follow-up time. In the univariate analysis, the 3-year PFS rates (83.7% vs 72.0%, *P* = 0.036) and 3-year LRFS rates (98.6% vs 90.2%, *P* = 0.034) were significantly higher for patients with the CCRT plus C arm than with CCRT alone. Furthermore, a marginal trend of increasing risk of 3-year DMFS rates (83.9% vs 78.4%, *P* = 0.301) and 3-year OS rates (91.2% vs 85.8%, *P* = 0.123) was found (Figure [1](#F1){ref-type="fig"}). The results of the multivariate analysis indicated that CCRT plus C treatment was a significant and independent protective predictor for 3-year PFS (HR = 1.26, 95% CI 1.164-2.789. *P* = 0.015) and LRFS rates (HR = 1.19, 95% CI 0.525-1.703. *P* = 0.047) (TABLE [2](#T2){ref-type="table"}).

Subgroup analysis
-----------------

When focusing on patients with stage T4 and/or N3 in the subgroup, the CCRT plus C arm achieved significantly prolonged 3-year PFS (79.9% vs 62.6%, *P* = 0.022) and a marginally increased OS (88.0% vs 77.9%, *P* = 0.086) (Figure [2](#F2){ref-type="fig"}) compared with that of CCRT alone arm. Additionally, the 3-year LRFS (97.0% vs 90.9%, *P* = 0.246) and DMFS (79.9% vs 67.8%, *P* = 0.161) were marginally enhanced in patients with CCRT plus C than in those with CCRT (Figure [2](#F2){ref-type="fig"}). The outcome of the multivariate analysis proved that cetuximab also reduced the risk of disease progression (HR = 2.34 CI 1.08-5.06, *P* = 0.031) (Table [3](#T3){ref-type="table"}).

When concentrating on stage III patients, there were no considerable statistically diversities found in 3-year PFS, OS, LRFS, and DMFS rates between patients with and without cetuximab treatment (Figure [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

Treatment toxicity
------------------

No treatment-related deaths occurred in this study. Acute toxic effects induced by the drugs of this study were mostly controllable and reversible. The most usually observed grade 3-4 hematological toxic effects were lymphopenia and neutropenia which were not normally accompanied by any vital infections. Chemotherapy induced pathognomonic toxic effects were rare. However, in the treatment with CCRT plus C, acneiform rash was the most usually observed grade 3-4 cetuximab-related toxicity. In 16 (21.3%) CCRT plus C patients, Dermatitis (radiation induced) was recorded as grade 3-4, which was more often than with CCRT alone 2 (1.3%, P\<0.001). A few patients had creatinine elevation or alanine transferase elevation in these two arms (Table [4](#T4){ref-type="table"}).

Late toxicities occurrence at the last follow-up were summarized in Table [4](#T4){ref-type="table"}. The most usually observed late toxic effects was Xerostomia. No cases of radiation-induced neuropathy were observed in this study. No significant difference was shown in the late toxicities of xerostomia, endocrine, neuropathy, sensorineural hearing loss, osteonecrosis, or radiation encephalopathy between the two treatment arms.

Discussion
==========

In the present study, we demonstrated that CCRT plus cetuximab was associated with significantly improved 3-year PFS (83.7% vs 71.9%) and LRFS rates (98.6% vs 90.2%) compared with CCRT alone in locoregionally advanced NPC, and this benefit mainly originated from patients with bulky lesions and/or extensive nodal diseases (T4 and/or N3). Presently, the propensity score-matching analysis, together with multivariate analysis, supplies the most objectively comparable results from matched patients with the treatment of CCRT with or without cetuximab to evaluate the efficacy of cetuximab.

EGFR is overexpressed and upregulated in more than 80% HNSCC tumors [@B20]. Cetuximab, an anti-EGFR monoclonal antibody, intensifies the sensitivity to chemotherapy and/or radiotherapy and the stimulation of antibody-dependent cellular cytotoxicity (ADCC) in HNSCC [@B21], [@B22]. In preclinical studies of HNSCC, several antitumor effects of cetuximab have been proved, those contain the inhibition of cell growth/survival and metastasis, angiogenesis [@B23]. Moreover, previous studies had been presented that cetuximab is safe and effective in locally advanced HNSCC patients. The advantage of combined strategies of cetuximab with RT regarding locoregional control (3 years, 47 % vs 34 %) and OS (5 years, 46 % vs 36 %) in locally advanced HNSCC was shown in Bonner\'s study [@B14]. When concomitantly delivered with RT in locally advanced HNSCC [@B14], it confirmed that cetuximab could significantly improve survival. Additionally, for patients with locoregionally advanced HNSCC, a randomized trial demonstrated that cetuximab plus radiotherapy considerably improved 5-year OS. It provided supplementary support for the current addition of cetuximab in the NCCN Guidelines as a recognized standard systemic treatment for locally advanced HNSCC patients [@B24]. Notwithstanding, for stage III-IV HNSCC patients in concurrent radiochemotherapy with or without cetuximab, phase III trial (RTOG 0522) [@B25], cetuximab could significantly improve the 2-year OS and PFS. Recently, researchers have begun to search for more combinations of therapies and subgroups that are sensitive to cetuximab [@B26].

Actually, it is confirmed that radiotherapy or chemotherapy combined with cetuximab has a higher tumor control rate and survival rate; this therapy strategy in HNSCC indicate the direction of NPC. However, it has to be analyzed prudently due to two types of tumors\' various biological behaviors. A preliminary Phase II clinical trial outcome was recorded by Ma et al [@B16], which is the first study to have incorporated cetuximab into chemoradiotherapy for locoregionally advanced NPC. The combination therapy led to a 2-year PFS of 86.5%, which was more effective than historic files according to the therapy without cetuximab (A 2-year PFS rate of 76% was reported in the same center). In this retrospective study, in order to decrease potential biases as much as possible, we used propensity score matching. In the propensity-matched cohort, the 3-year PFS rate (83.7% vs 72.0%, *P* = 0.036) and 3-year LRFS rate (98.6% vs 90.2%, *P* = 0.034) of the patients with CCRT plus C were considerably better compare with those with CCRT alone. Furthermore, our data showed that 3-year DMFS rate (83.9% vs 78.4%, *P* = 0.301) and 3-year OS rates (91.2% vs 85.8%, *P* = 0.123) were marginally improved, although no significant difference between the 2 treatments was observed with regard to the rates of DMFS and OS. However, from the addition of cetuximab to the CCRT in locoregionally advanced NPC, patients with T4 and/or N3 could gain greatly improve. We found that the OS was enhanced by above 10% in the subgroup of T4 and/or N3 stage with the regimen of CCRT plus C, although there were statistically insignificant differences. Furthermore, considerably lower risk of tumor progression and marginal progress in LRFS and DMFS were observed. Recently, Zhang et al.[@B27] reported survival rates in locoregionally advanced NPC rose by helical tomotherapy plus cetuximab, then introduced TP adjuvant chemotherapy. Moreover, cetuximab accompanied with chemoradiotherapy was well tolerated and effective in the treatment of metastatic nasopharyngeal carcinoma or recurrent [@B28]. Nevertheless, Xu et al.[@B29] showed that cetuximab radiotherapy did not enhance the 3-year OS compared with cisplatin-chemoradiotherapy in locoregionally advanced NPC. Wu et al.[@B30] evaluated cetuximab-radiotherapy was not inferior to traditional CR in a retrospective study,. These results are markedly different from ours, since these 2 studies enrolled mostly stage II/III patients. In our study, we observed that there were no statistically significant differences in 3-year PFS, OS, LRFS, and DMFS rates between the 2 groups, and patients with stage III were less likely to benefit from CCRT plus C. To the best of our knowledge, this is the first research reporting that a combination of cetuximab and CCRT can significantly increase PFS and OS in patients with stage T4 and/or N3 but rarely benefits stage III NPC patients.

We observed that oral and oropharyngeal mucositis were the most common acute toxic effects. Hematologic toxicity was not different between the two groups. No treatment-related deaths occurred. Moreover, our previous study reported more acute moderate to severe toxicities and dermal toxicities and oral mucosal responses in particular. This adverse reaction was specific to cetuximab and more toxic in combination with radiochemotherapy. Nevertheless, cetuximab and CCRT of locoregionally advanced NPC is effective and tolerant [@B17]. When contrast the concurrent RT plus cisplatin (either IMRT or 2D-RT), Ma et al. showed a comparatively high percentage of RT-related mucosal toxic effects and acute skin [@B16]. Another study presented that concurrent treatment of RT, cisplatin, and cetuximab, was a feasible strategy against locoregionally advanced NPC, which also showed the mucosal and skin toxic effects were controllable, improvable and invertible[@B31]. It has even been found that the head and neck carcinoma patient who had grade 2-4 cetuximab rash was normally observed higher survival rate [@B32]. Additionally, during this study, the recorded late toxic effects were normally grade 1-2 in severity; no significant difference was observed in the late toxicities. They were similar as the recorded respective rate in the study by Zeng et al [@B33].

By propensity score matching and multivariate analysis, with the largest sample size analysis of the CCRT plus C effect in locoregionally advanced NPC, it demonstrates main advantage of this study. The restriction of correlative selection bias and divergent confounders from retrospective assessment of observational data has been exceedingly improved by this method. In spite of the statistics were collected from one single institution, they supplied beneficial advices on the CCRT plus C impact prior to a concluding report of any Phase III randomized controlled trial.

Our study has several limitations. The innate limitation of this single institutional retrospective study has been recognized. Due to in many circumstances, statistics on the EB - DNA copy number could not be located and recorded, they were replaced by EBV-EA-Ig A and EBV-VCA-Ig A. Therefore, in this retrospective study, it was difficult to acquire extensive toxicity statistics. Furthermore, a chosen group of malignant cases statistics is presented in this dissertation since there was no clinical trial applied toward these patients. Finally, it is necessary to interpret our results prudentially due to the relatively short follow-up time.

Conclusion
==========

This propensity-matched study reveals that patients with T4 and/or N3 stage could benefit from the combination of cetuximab with the current chemoradiotherapy in locoregionally advanced NPC, although with more acute moderate to severe toxicities. However, this strategy remains to be validated in a prospective randomized controlled study.
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###### 

Baseline characteristics of nasopharyngeal carcinoma patients who underwent chemoradiotherapy with or without cetuximab

                       Before propensity score matching   After propensity score matching                                                          
  -------------------- ---------------------------------- --------------------------------- ------- ------ --------- ------- ------ ------- ------ -------
  **Age**                                                                                                  \<0.001                                 0.894
  Mean                 47.41                                                                50.36                    47.41          47.86          
  SD                   10.70                                                                11.9                     10.70          10.45          
  Median               47.00                                                                50.00                    47.00          47.00          
  **Sex**                                                                                                  0.457                                   0.615
  Male                 61                                 81.3                              470     77.6             61      81.3   126     84.0   
  Female               14                                 18.7                              136     22.4             14      18.7   24      16.0   
  **BMI**                                                                                                  0.361                                   0.890
  Mean                 22.6                                                                 22.4                     22.6           22.6           
  SD                   3.2                                                                  3.5                      3.2            2.9            
  Median               22.5                                                                 22.3                     22.5           22.5           
  **Histology^a^**                                                                                         0.089                                   0.380
  I+II                 1                                  4.0                               37      4.8              1       4.0    5       3.3    
  III                  74                                 96.0                              569     95.2             74      96.0   145     96.7   
  **EA-lgA^b^**                                                                                            0.034                                   0.340
  \<10                 14                                 18.7                              187     30.9             9       12.0   24      16.0   
  10-40                25                                 33.3                              210     34.7             29      38.7   44      29.3   
  ≥40                  36                                 48.0                              209     34.5             37      49.3   82      54.7   
  **VCA-lgA^b^**                                                                                           0.090                                   0.709
  \<80                 10                                 13.3                              120     19.8             10      13.3   25      16.7   
  80-320               22                                 29.3                              218     36.0             22      29.3   47      31.3   
  ≥320                 43                                 57.3                              268     44.2             43      57.3   78      52.0   
  **T-stage**                                                                                              0.004                                   0.987
  T1                   8                                  10.7                              22      3.63             8       10.7   14      9.3    
  T2                   10                                 13.3                              43      7.10             10      13.3   19      12.7   
  T3                   26                                 34.7                              291     48.0             26      34.7   54      36.0   
  T4                   31                                 41.3                              250     41.3             31      41.3   63      42.0   
  **N-stage**                                                                                              0.033                                   0.994
  N0                   3                                  4.0                               51      8.42             3       4.0    7       4.7    
  N1                   29                                 38.7                              302     49.8             29      38.7   59      39.3   
  N2                   31                                 41.3                              202     33.3             31      41.3   60      40.0   
  N3                   12                                 16.0                              51      8.42             12      16.0   24      16.0   
  **Clinical stage**                                                                                       0.085                                   1.000
  III                  38                                 50.7                              312     51.5             38      50.7   76      50.7   
  IVa                  25                                 33.3                              243     40.1             25      33.3   50      33.3   
  IVb                  12                                 16.0                              51      8.42             12      16.0   24      16.0   

Abbreviations: CCRT = concurrent chemoradiotherapy, C = cetuximab, SD = standard deviation, BMI = body mass index, VCA = viral capsid antigen, lgA = immunoglobulin A, EA = early antigen.

a Based on the criteria of WHO histological type (1991): I - Keratinising squamous-cell carcinoma, II - Differentiated non-keratinising carcinoma, III - Undifferentiated non- keratinising carcinoma.

^b^ In accordance with the criteria adopted in previous studies.

^c^ Used Fisher\'s exact test.

###### 

Summary of important prognostic factors in the multivariate analysis in the propensity-matched cohort.^a^

                                           Hazard ratio (95% CI)   *P*
  ---------------------------------------- ----------------------- ---------
  **Progressive-free survival**                                    
  CCRT+C versus CCRT                       1.26 (1.16-2.79)        0.015
  Sex                                      0.51 (0.25-1.05)        0.069
  Age (continuous)                         0.80 (0.46-1.38)        0.071
  BMI (continuous)                         1.04 (0.79-2.87)        0.130
  Clinical stage                           1.40 (1.23-1.90)        \<0.001
  T-stage                                  1.21 (1.17-1.86)        0.023
  N-stage                                  1.46 (1.53-2.26)        0.015
  **Overall survival**                                             
  CCRT+C versus CCRT                       1.14 (0.83-3.87)        0.109
  Sex                                      0.40 (0.15-1.05)        0.162
  Age (continuous)                         0.65 (0.32-1.30)        0.068
  BMI (continuous)                         0.74 (0.49-1.87)        0.072
  Clinical stage                           1.32 (1.16-2.45)        \<0.001
  T-stage                                  1.76 (1.29-2.37)        0.007
  N-stage                                  2.04 (1.53-2.59)        0.001
  **locoregional relapse-free survival**                           
  CCRT+C versus CCRT                       1.19 (0.53-1.70)        0.047
  Sex                                      0.62 (0.21-1.87)        0.242
  Age (continuous)                         0.58 (0.33-1.15)        0.264
  BMI (continuous)                         0.82 (0.41-1.38)        0.108
  Clinical stage                           1.53 (0.91-2.43)        0.075
  T-stage                                  1.97 (1.32-2.81)        0.013
  N-stage                                  0.78 (0.21-1.36)        0.569
  **Distant metastasis-free survival**                             
  CCRT+C versus CCRT                       0.76 (0.77-1.98)        0.242
  Sex                                      0.96 (0.52-1.77)        0.694
  Age (continuous)                         0.71 (0.47-1.30)        0.145
  BMI (continuous)                         0.43 (0.37-1.04)        0.127
  Clinical stage                           1.22 (0.62-1.16)        0.001
  T-stage                                  0.53 (0.30-1.45)        0.116
  N-stage                                  2.24 (1.14-2.76)        \<0.001

Abbreviations: CI = confidence interval, CCRT = concurrent chemoradiotherapy, C = cetuximab, BMI = body mass index.

^a^ Adjusted for clinical stage, T-stage, and N-stage with Enter method, sex, age(continuous) and BMI(continuous) with Backward LR method.

###### 

Subgroup analysis by prognostic factors in the multivariate analysis in the propensity-matched cohort.^a^

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           N\          Progressive-free survival           Overall survival           Locoregional relapse-free survival           Distant metastasis-free survival   
                           (CCRT+C\                                                                                                                                                   
                           vs CCRT)                                                                                                                                                   
  ------------------------ ----------- --------------------------- ------- ------------------ ------- ------------------------------------ ------- ---------------------------------- -------
  **Age**                                                                                                                                                                             

  \<45 ys                  28 vs 54    1.34 (0.58-1.46)            0.143   0.58 (0.63-1.93)   0.247   1.18 (0.32-1.73)                     0.165   1.24 (0.61-1.47)                   0.420

  ≥ 45ys                   47 vs 96    1.79 (0.89-2.08)            0.058   0.81 (0.73-1.57)   0.233   1.31 (0.61-1.81)                     0.087   1.07 (0.63-2.19)                   0.483

  **Sex**                                                                                                                                                                             

  Male                     61 vs 121   1.39 (0.32-2.11)            0.047   1.06 (0.76-1.48)   0.215   1.43 (0.42-1.29)                     0.046   1.22 (0.63-2.10)                   0.554

  Female                   14 vs 29    1.15 (0.48-1.67)            0.356   0.58 (0.21-1.64)   0.670   0.50 (0.26-0.95)                     0.150   1.08 (0.61-1.89)                   0.781

  **Stage**                                                                                                                                                                           

  III                      38 vs 76    0.67 (0.414-2.87)           0.409   1.32 (0.77-2.25)   0.676   0.67 (0.41-2.87)                     0.105   0.84 (0.28-2.52)                   0.756

  T4 and/or N3 (IVa+IVb)   37 vs 74    2.34 (1.08-5.06)            0.031   2.07 (0.84-2.29)   0.110   1.26 (0.57-1.84)                     0.049   0.69 (0.38-2.14)                   0.181

  N3 (IVb)                 12 vs 24    1.85 (0.39-2.42)            0.487   1.86 (0.61-1.98)   0.045   1.36 (0.53-4.20)                     0.489   1.53 (0.21-2.64)                   0.292
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CCRT = concurrent chemoradiotherapy, C= cetuximab, CI = confidence interval.

^a^ Adjusted for clinical stage with Enter method, age and sex with Backward LR method.

###### 

Incidence of major acute and late toxicities in the propensity matched cohort.^a^

  ----------------------------------------------------------------------------------------------------------------
  Toxicity                         CCRT+C (n = 75)\      CCRT (n = 150)\       *P* value                 
                                   No. of patients (%)   No. of patients (%)                             
  -------------------------------- --------------------- --------------------- ------------- ----------- ---------
  **Acute toxicities**                                                                                   

  Hematologic                                                                                            

  Neutropenia                      37 (49.3)             38 (50.7)             83 (55.3)     67 (44.7)   0.400

  Leucopenia                       35 (46.7)             40 (53.3)             82 (54.7)     68 (45.3)   0.262

  Thrombocytopenia                 73 (97.3)             2 (2.7)               149 (99.3)    1 (0.7)     0.258

  Anemia                           74 (98.7)             1 (1.3)               150 (100.0)   0 (0.0)     0.333

  **Non-hematologic**                                                                                    

  Acneiform rash                   64 (85.3)             11 (14.7)             150 (100.0)   0 (0.0)     \<0.001

  Dermatitis (radiation induced)   59 (78.7)             16 (21.3)             148 (98.7)    2 (1.3)     \<0.001

  Oral mucositis                   25 (33.3)             50 (66.7)             135 (90.0)    15 (10.0)   \<0.001

  Vomiting                         67 (89.3)             8 (10.7)              150 (100.0)   0 (0.0)     \<0.001

  Weight loss                      60 (80.0)             15 (20.0)             128 (85.3)    22 (14.7)   0.342

  Creatinine elevation             75 (100.0)            0 (0.0)               150 (100.0)   0 (0.0)     1.000

  Alanine transferase elevation    75 (100.0)            0 (0.0)               149 (99.3)    1 (0.7)     1.000

  **Late toxicities**                                                                                    

  Xerostomia                       65 (86.7)             10 (13.3)             128 (85.3)    22 (14.7)   1.000

  Endocrine                        74 (98.7)             1 (1.3)               147 (98.0)    3 (2.0)     1.000

  Neuropathy                       75 (100.0)            0 (0.0)               150 (100.0)   0 (0.0)     1.000

  Sensorineural hearing loss       75 (100.0)            0 (0.0)               148 (98.7)    2 (1.3)     0.554

  Osteonecrosis                    75 (100.0)            0 (0.0)               149 (99.3)    1 (0.7)     1.000

  Radiation encephalopathy         73 (97.3)             2 (2.7)               145 (96.7)    5 (3.3)     1.000
  ----------------------------------------------------------------------------------------------------------------

Abbreviations: CCRT = concurrent chemoradiotherapy, C = cetuximab.

^a^ Used Fisher\'s exact test.
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